Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Eprotirome (KB2115) 是一种肝脏选择性甲状腺激素受体 (thyroid hormone receptor, TR) 激动剂。它对 TRβ的亲和力略高于TRα。它降低了低密度脂蛋白 (LDL) 胆固醇的浓度,可用于研究血脂异常和肥胖症。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 218 | 现货 | ||
2 mg | ¥ 297 | 现货 | ||
5 mg | ¥ 497 | 现货 | ||
10 mg | ¥ 788 | 现货 | ||
25 mg | ¥ 1,580 | 现货 | ||
50 mg | ¥ 2,490 | 现货 | ||
100 mg | ¥ 3,990 | 现货 | ||
500 mg | ¥ 8,490 | 现货 |
产品描述 | Eprotirome (KB2115), a synthetic thyroid hormone mimetic, is a thyroid hormone receptor agonist. |
体内活性 | In moderately overweight and hypercholesterolemic subjects Eprotirome (KB2115) was found to be safe and well tolerated and elicited up to a 40% lowering of total and LDL cholesterol after 14 days of treatment. Bile acid synthesis was stimulated without evidence of increased cholesterol production [1]. KB2115 treated mice exhibited increased fasting glucose, although KB2115 did not increase fasting insulin levels [2]. |
动物实验 | A catheter was implanted into the right internal jugular vein before the hyperinsulinemic-euglycemic clamp. After recovery, mice were administered GC-1 (0.03 or 0.3 mg/kg), KB2115 (0.3 mg/kg) or T3 (0.06 mg/kg) via intraperitoneal injection for 10 days. On the day of the clamp experiment, conscious, overnight-fasted mice received a primed (10 μCi) and constant rate intravenous infusion (0.1 uCi/min) of [3-3H] glucose to measure basal glucose turnover. After 60–75 minutes of labeled glucose infusion, the hyperinsulinemic-euglycemic clamp was performed with continuous infusion of insulin (12 mU/kg/min) and variable infusion of 25% glucose to maintain euglycemia (~120 mg/dl). Blood samples were collected by tail bleeding (approximately every 10 min) to measure blood glucose concentrations [2]. |
别名 | 伊罗替罗, KB2115 |
分子量 | 487.14 |
分子式 | C18H17Br2NO5 |
CAS No. | 355129-15-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 30 mg/mL
DMSO: 90 mg/mL (184.75 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.0528 mL | 10.264 mL | 20.528 mL | 51.3199 mL |
5 mM | 0.4106 mL | 2.0528 mL | 4.1056 mL | 10.264 mL | |
10 mM | 0.2053 mL | 1.0264 mL | 2.0528 mL | 5.132 mL | |
20 mM | 0.1026 mL | 0.5132 mL | 1.0264 mL | 2.566 mL | |
50 mM | 0.0411 mL | 0.2053 mL | 0.4106 mL | 1.0264 mL | |
100 mM | 0.0205 mL | 0.1026 mL | 0.2053 mL | 0.5132 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Eprotirome 355129-15-6 Endocrinology/Hormones Thyroid hormone receptor(THR) THR inhibit KB 2115 伊罗替罗 Inhibitor KB-2115 KB2115 Thyroid Hormone Receptor inhibitor